Yosemite

Established in 2023 and headquartered in San Francisco, Yosemite is a venture capital firm focusing on early-stage investments within the healthcare sector.

Reed Jobs

Founder

5 past transactions

Daymark Health

Seed Round in 2025
Daymark Health is a healthcare company specializing in supportive care services for cancer patients. It connects primary care physicians, oncologists, and care teams to provide virtual and home-based care, symptom management, care navigation, social support, and mental health services. These services are delivered by nurse practitioners, social workers, and health partners, ensuring comprehensive, personalized care that addresses both medical and non-medical needs throughout the patient's treatment journey.

Tune Therapeutics

Series B in 2025
Tune Therapeutics develops cell and gene therapies guided by epigenetic programming to treat devastating diseases. The company is building an epigenetic programming platform that enables new pathways for disease treatment by tapping into the epigenome to program biology without altering the DNA sequence. This approach aims to deliver paradigm-changing therapies by modulating gene expression through epigenetic mechanisms rather than editing the genome, expanding options for diseases where conventional treatments have limited efficacy. By integrating epigenetics and cell biology, the company seeks durable, precise interventions that can reprogram cellular states to restore function while minimizing genetic change. The emphasis is on research and development to advance candidates toward clinical use to address severe and unmet medical needs.

Shinobi Therapeutics

Series A in 2024
Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

Turquoise Health

Series B in 2024
Turquoise Health is a health tech company focused on simplifying healthcare administration to lower costs and reduce complexity. By leveraging data from hospital and payer machine-readable files, Turquoise Health has developed a platform that enables users to browse and compare prices for elective services offered by hospitals. The platform facilitates price comparisons between various insurance services and allows individuals to search by procedure and provider. This innovative marketplace connects patients, providers, and payers, empowering individuals to save money on elective treatments while helping healthcare organizations attract both cash-paying and insured patients.

Maia Oncology

Seed Round in 2023
Maia Oncology operates a virtual cancer care coordination platform, serving as a comprehensive primary care clinic for cancer patients and survivors. The platform tracks patient outcomes, including hospitalizations, ER visits, and new comorbidities, enabling patients to navigate cancer-related toxicities and long-term complications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.